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Summary: Effect of interaction of melatonin and caffeine on caffeine induced oxidative stress and sleep disorders was 
studied. Fifteen wistar rats were randomly assigned into three study groups. The animals in group 1 (the control) received a 
placebo of 10.0 ml distilled water via gastric intubation. The hosts in groups 2 and 3 were treated with 100 mg caffeine/ kg, 
or melatonin/ kg, respectively, in a total volume of 10.0 ml vehicle. The experiment lasted for 30 days. One day after the 
final exposure, the animals were euthanized by inhalation of overdose of chloroform. Blood was collected by cardiac 
puncture. Serum was obtained by centrifugation (6000 Xg, 30 mins), and used for serum total protein and serum blood urea 
nitrogen levels. The brain of each rat was also harvested and processed into whole homogenate, frozen in liquid nitrogen 
(N2), and maintained at -80oC until used for total brain cholesterol and tryptophan levels. The results showed that 
interaction of melatonin and caffeine enhanced protein synthesis; stimulated gonadotrophin release,  and could be used as 
oral contraceptive for women, and may be beneficial in the treatment of impotence (androgen depression), leading to 
improved reproductive and sex life; stimulated tryptophan metabolism, which prevents vitamin B6 deficiency, anemia, 
negative nitrogen balance, tissue wasting and accumulation of xanthurenic acid, which promotes sleep; and could be 
beneficial in the treatment of hyper cholesterolemia, thereby preventing coronary heart disease, and post menopausal 
osteoporosis. 
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Caffeine, 1, 3, 7 – trimethylxanthine is consumed 
worldwide by people of all races and social class 
through processed cocoa, coffee, tea or kolanut based 
foods and beverages, stimulants, drugs and cosmetics 
(Eteng et al, 1997; Obochi, 2006). Caffeine, 
theophyllines and theobromines are related 
compounds and are classified as alkaloids. An 
alkaloid is a compound that contains nitrogen, and is 
physiologically active. Caffeine is metabolized in the 
liver and is excreted in kidneys, faces, saliva, semen 
and breast milk (Julien, 1996). Liver diseases, 
pregnancy, and use of oral contraceptives slow the 
metabolism and excretion while nicotine and other 
therapeutic drugs interact with caffeine to increase or 
decrease its metabolism and excretion (Julien, 1996). 
Caffeine is equally distributed in total body water and 
freely crosses the placenta to the fetus, leading to 
spontaneous abortion or miscarriage (Julien, 1996). 
The metabolism and toxicity of caffeine are viewed to 
be dose dependent, resulting in non-linear 
accumulation of metabolites (Methylxanthines – 
dimethyluric acid, 7-methyl uric acid, 3-methyluric 
acid), which may lead to cardiovascular diseases such 
as heart failure, high blood pressure and neuronal 
disorder as schizophrenia (Julien, 1996; Eteng et al, 
1997; Obochi, 2006). 
 The central nervous system stimulatory action of 
caffeine elevates mood. This accounts for much of the 
popularity that coffee and tea have as morning wake-
up beverages. Also, people who are afflicted with 
significant depression medicate themselves by using 
caffeine products. Caffeine acts to block adenosine’s 
inhibition of cells in the brain, and this underlies 
alertness and up beat mood (Julien, 1996). Adenosine 
is an inhibitory neurotransmitter, synthesized from 
AMP by the action of s-nucleotidase, which acts to 
result in behavioural sedation, regulation of oxygen 
delivery to cells, dilation of cerebral and coronary 
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blood vessels (Eteng et al, 1997). Caffeine and other 
methylxanthines occupy adenosine receptors and then 
block the action of the neurotransmitter. Adenosine 
receptors are linked with interplay of release, 
reuptake, metabolism and excretion of 
neurotransmitters (Julien, 1996; Eteng et al, 1997; 
Obochi, 2006). Thus, blockade of adenosine receptors 
by caffeine results in alteration in behavioural pattern 
by delaying neuronal tube closure (Eteng et al, 1997); 
activates phosphorylase and lipase, thereby enhancing 
glycogenolysis and lipolysis, resulting in loss of 
weight (Julien, 1996). The blockade also inhibits 
glutamate release, resulting in low protein synthesis, 
poor growth, low protein efficiency ratio, poor 
nitrogen retention (Eteng et al, 1997), and decreases 
bone mineral density, leading to osteoporosis, 
palpitations, tremor, headache, anxiety, peptic ulcer 
and insomnia (Julien, 1996). The blockade of 
adenosine receptors by caffeine inhibits androgen 
binding protein, resulting in decreased cauda 
epididymis sperm reserve, seminiferous tubular fluid 
volume, low sperm production and infertility (Eteng 
et al, 1997; Obochi, 2006). Thus, the toxicity of 
caffeine is viewed as a phenomenon of rapid 
absorption but slow excretion (Obochi, 2006).  
 Therapeutic properties of caffeine include relief of 
pain, headache and cold (through inhibition of the 
inflammatory action of prostaglandins), depression 
and in appetite-suppressant medications due to its 
diuretic effects (Obochi, 2006). Melatonin (N-acetyl-
5-mehoxytryptamine is a hormone synthesized from 
tryptophan in the pineal gland of the brain in humans 
and animals (Reiter, 1995); stimulated by the dark 
and inhibited by light (Reiter, 1995). It also occurs 
naturally in plants such as oats, tomatoes, banana and 
barley (Webb and Pulg-Domingo, 1995). The 
principal role of melatonin involves regulation of 
neuro-endocrine reproductive functions (Reiter et al, 
1995; Webb and Pulg-Domingo, 1995). It also plays a 
role in signaling changes in reproductive hormone 
levels (Maestroni, 1993). Melatonin is metabolized to 
6-hydroxy-melatonin in the liver, and the main 
metabolite, 6-sulphatoxy-melatonin is excreted 
(Maestroni, 1993; Cavallo, 1993); lowers body 
temperature and blood flow to the brain, (Lamberg, 
1996; Brzezinski, 1997).  
 Melatonin is an effective antioxidant that protects 
DNA, cells and tissues from free radical assault 
(Sharma et al, 1989; Stokkan et al, 1991; Pierpaoli et 
al, 1993; Tan et al, 1993; Lesnikov et al, 1994; 
Pierpaoli et al, 1994; Reiter, 1995). It stimulates the 
main antioxidant ezyme of the brain, glutathione 
peroxidase (Reiter, 1995) and inhibits proliferation 
and growth of cancer cells (Blask et al, 1991; Lissoni 
et al, 1992; Cos et al, 1994; Neri et al, 1994; Aldeghi 
et al, 1994; Lissoni et al, 1994; Sandyk, 1994; Chan 
et al, 1995; Lissoni et al, 1995). It also lowers total 
cholesterol and LDL levels in rats (Chan et al, 1995); 
acts as a powerful chronobiotic maintaining 
synchronicity and preventing desynchrony of 
circadian rhythms (Armstrong, 1989; Attenburrow et 
al, 1996); improves sleep (Garfinkel et al, 1995) and 
sex life (Laudon et al, 1988). 
 Melatonin stimulates gonadotrophin release 
hormone, estrogen levels and androgen responses 
(Terzollo et al, 1993; Laudon et al, 1996), and may 
inhibit ovarian function in women and may be 
beneficial as oral contraceptive (Voordouw et al, 
1992). It is involved in the regulation of calcium and 
phosphorous metabolism by stimulating the 
parathyroid gland and by inhibiting calcitonin release 
and prostaglandins synthesis (Sandyk et al, 1992). 
Melatonin stimulates immunoenhancing effects 
(Maestroni, 1993), improves leucopenia and winter 
depression (Neri et al, 1994; Webb and Pulg-
Domingo, 1995). Because of these therapeutic 
properties of melatonin, it is often bought over the 
counter in health food shops and is consumed for 
improved sleep, sex life, longevity and lowering of 
blood pressure, leading to self medication. The 
current study is therefore focused on assessment of 
how melatonin could impact upon caffeine induced 
oxidative stress and sleep disorders in animals 
exposed daily to caffeine and melatonin. 
 
 
MATERIALS AND METHODS 
 
 Fifteen Wistar albino rats weighing between 150g 
to 250g obtained from the disease free stock of the 
animal house, Department of Biochemistry, College 
of Medical Sciences, Benue State University, 
Makurdi, Nigeria, were used for the study. The 
animals were randomly assigned into three study 
groups of five animals per group. Each rat in a study 
group was individually housed in a stainless  steel 
cage with plastic bottom grid and a wire screen top. 
The animal room was adequately ventilated, and kept 
at a room temperature and relative humidity of 29 ± 
2oC and 40 – 70% respectively with 12 hour natural 
light-dark cycle. The animals were fed ad libitum 
with water and rat chow (Livestock Feeds Ltd, 
Makurdi, Nigeria). Good hygiene was maintained by 
constant cleaning and removal of faeces and spilled 
feeds from cages daily. All animal experiments were 
approved by the Animal Care and Use Committee of 








 All rats received daily treatment with their test 
solutions for a period of 30 days. All treatments were 
conducted between the hours of 6.00 – 7.00 pm 
because melatonin is most active in the evening. The 
rats in Group 1 (the control) received a placebo of 
4.0ml distilled water by gastric intubation. The rats in 
Groups 2 and 3 were treated with 100mg caffeine/kg 
body weight or a combination of 100mg caffeine/kg 
body weight + 100mg melatonin/kg body weight, 
respectively, in a total volume of 4.0ml vehicle. 
 
Preparation of caffeine 
 Synthetic caffeine was obtained from May and 
Baker (M & B) Limited (Enfield, Middlesex, 
England), and used for the study. A stock solution of 
caffeine was prepared by dissolving 20g of powdered 
caffeine in 500ml of hot distilled water. The solution 
was allowed to cool to room temperature, and from 
this, and based on the animal’s weight that morning, 
the 100mg/kg body weight dosages were 
administered to the animals in Groups 2 and 3 as part 
of the 10.0ml volume used for gastric intubation. 
 
Preparation of Melatonin 
 Synthetic melatonin was obtained from May and 
Baker Limited (Enfield, Middlesex, England), and 
used for the study. A stock solution of melatonin was 
prepared by powdered melatonin in 500ml of distilled 
water. From this, and based on the animal’s weight 
that morning, the 100mg/kg body wieght dosages 
were administered to the animals in Groups 3 as part 
of the 10.0ml used for gastric intubation. 
 
Sample preparation 
 One day after the final exposure, the animals were 
euthanized by inhalation of overdose of chloroform. 
Blood was collected by cardiac puncture. Serum was 
obtained by centrifugation (6000 Xg, 30min.), and 
used for serum total protein, blood urea nitrogen 
levels. The brain of each rat was also harvested and 
processed into whole homogenate. Briefly, the brain 
tissues were ground using mortar and pestle, and 
buffered with Tris-HCl (pH 7.4). a whole homogenate 
(WH) of the tissue was then prepared by 
centrifugation at 6000 Xg for 30min; the supernatant 
generated was recovered and subjected to a second 
centrifugation at 8000 Xg for 20min. The whole 
homogenate (WH) was then frozen in liquid nitrogen 
(N2) and maintained at -80oC until used for total brain 
cholesterol and tryptophan levels. 
 
Determination of Total Serum Protein Level  
 Total serum protein was determined by the Biuret 
method described by Gornall et al (1949). To 0.5ml 
of the sample solution was added 1.0ml distilled 
water to bring the volume to 1.5ml in each tube. Tube 
1, the blank received 1.5ml distilled wate. The 
suspension was mixed, and 0.2ml of 5% sodium 
deoxycholate (DOC) in 0.01N KOH was added and 
mixed to make the suspension more soluble. Then, 
1.5ml of biuret reagent (1.50g CuSO4 ∙ 5H2O, 6.0g 
Sodium potassium tartrate, and 300ml of 10% NaOH 
per litre) was added (including the blank). The 
contents in each tube were mixed in a vortex mixer, 
and incubated at 37oC for 15 min, and the 
absorbances read at 50nm in a 6400/6405 
spectrophotometer (Jenway, Essex, England) against 
the reaction blank. The concentration of the standard 
bovine serum albumin (BSA) was 2mg/ml (1.0g BSA 
was dissolved in 500ml H2O). 10% NaOH was 
prepared by dissolving 100g NaOH in 1 litre of 
distilled water. 
 
Determination Of Blood Urea Nitrogen Levels 
 Serum blood Urea nitrogen was determined with 
the method of Taylor (1989). In this assay, Urea, the 
end product of nitrogen metabolism in humans is 
hydrolysed to ammonia (NH3) and carbon dioxide 
(CO2) by an enzyme, urease. The ammonia is then 
converted to indophenol blue in the presence of 
sodium nitroferricyanide, phenol and alkaline 
hypochlorite reagents. Briefly, 10ml of the EDTA 
(dissolved 7.5g EDTA- free acid in 400ml H2O, pH 
adjusted to 6.5 with 10% NaOH, and diluted to 
750ml) buffered serum were pipetted into 13 X 
100mm test tubes, and 10ml distilled water added to 
bring the volume to 20ml. The blank tube received 
20ml distilled water. Then, 20ml of urease solution 
(5ml urease-glycerol extracts in 100ml volumetric 
flask, and diluted to 100ml with EDTA buffer) was 
added to all tubes including the blank. The tubes were 
incubated at 37oC for 30min. Then, 0.5ml of phenol 
reagent [5ml of liquefied Phenol to 100ml volumetric 
flask, added 80ml H2O and 1.0ml of 2.5% sodium 
nitroferricyanide stock solution (prepared by 
dissolving 2.5g Na nitroferricyanide in 100ml H2O) 
and brought to volume with H2O] was added to all 
tubes. Then, 0.5ml of alkaline hypochlorite reagent 
[mix 25ml of 2.5N NaOH (10%) and 4.0ml Clorox, 
and diluted to 100ml with H2O] was added to all 
tubes. The tubes were mixed, and incubated at room 
temperature for 40 min. then, 4.0ml distilled water 
added to all tubes, mixed and the absorbencies read at 
625 nm in a 6400/6405 spectrophotometer (Jenway, 
Essex, England). 0.2mg/ml urea working standard 
was prepared by adding 2.0ml stock solution to 98ml 
H2O. 10.0mg/ml urea stock standard was prepared by 
dissolving 2.14g Urea in 100ml H2O, and freeze in 
2.5ml batches. 




Determination Of Total Brain Cholesterol Levels 
 
 Total brain cholesterol was determined with the 
method of Kates (1986). Briefly, 1.0ml of the whole 
homogenate (WH) were pipetted, and evaporated to 
dryness in small test tubes under nitrogen (N2). The 
dried samples were redissolved in absolute ethanol. 
Then, 0.1ml of the WH was delivered using an 
automatic micropipettor into tubes and sufficient 
absolute ethanol added to bring the volume to 2.0ml. 
2.0ml absolute ethanol only was used for the blank. 
Then, 1.0ml of the cholesterol reagent [add 40ml iron 
stock reagent (prepared by dissolving 5.0g FeCl3 ∙ 
6H2O in 200ml conc. H3PO4) to 460ml conc. H2SO4] 
was added to all tubes. Then, 2.0ml of ferric chloride 
reagent (consists of 80ml of a solution of 2.5% FeCl3 
∙ 6H2O in conc. H3PO4 and 920ml of conc. H2SO4 per 
litre) was added, and mixed carefully at the lowest 
setting of the vortex mixer. The tubes were incubated 
for 30 min. at room temperature, and the absorbencies 
read at 550nm in 6400/6405 spectrophotometer 
(Jenway, Essex, England). The concentration of the 
cholesterol standard solution was 0.1mg/ml (dilute 
5.0ml of cholesterol stock solution in 50ml absolute 
ethanol). Cholesterol stock standard was prepared by 
dissolving 0.1g cholesterol in 100ml absolute ethanol. 
 
Determination of total brain tryptophan Levels 
 Total brain tryptophan was isolated and 
determined according to the standard method 
described by Davidson and Henry (1979). Briefly, in 
the isolation assay, 1.0ml of the brain whole 
homogenate (WH) were pipetted into 20ml ample, 
9.0ml of 6.0N NaOH added, mixed, and the ampule 
sealed by pulling the glass tip over an intense flame. 
The suspension was incubated at 110oC for 24 hours. 
The extracts were transferred to 50ml beakers; each 
titrated with 6N HCl to pH 7.0 while mixing on a 
magnetic stirrer. The titration was then changed to 1N 
HCl at a pH 8.5, and centriguged at 10,000 Xg for 
20min. the supernatant was decanted into 25ml 
graduated cylinders, and the volumes brought to 20ml 
with 0.1M Tris-HCl buffer, pH 7.4, and mixed well. 
The hydrolysate (whole homogenate-WH) was used 
for the analysis of total tryptophan levels. 
 In the determination assay, briefly, whole sample 
homogenates were pipetted into test tubes. The blank 
received 1.0ml distilled water. Then, 5.0ml of 
tryptophan free growth medium (10.5g K2HPO4, 1.0g 
(NH4)2SO4, 1.0g Na citrate ∙ 2H2O, 0.65g MgSO4, 
2.0g glucose per litre) was added to all tubes 
including the blank. Then, 5.0ml of 4% glucose 
solution was added. The tubes were autoclaved for 
15min (120oC, 15-1b pressure). All the tubes were 
allowed to cool to room temperature, and incubated in 
a shaking water bath at 37oC for 48 hours. The tubes 
were mixed vigorously in a vortex mixer, and the 
absorbances read at 450nm in 6400/6405 




 Data collected were expressed as mean ± standard 
deviation (SD), and the Student’s  
t- test was used for analysis. Values of P < 0.05 were 





 Table 1 presents the results of treatments on total 
serum protein and blood serum urea nitrogen levels in 
the rats. The results of the total serum protein levels 
showed that there was significant (P < 0.05) increase 
(12.66%) in the values of the caffeine treated hosts, 
and a significant (P < 0.05) increase (45.11%) in the 
values of the melatonin + caffeine treated animals, 
relative to those seen in the controls. 
 The result of treatments on blood serum urea 
nitrogen levels showed that there was significant (P < 
0.05) increase (99.63%) in the values of the caffeine 
treated rats relative to the controls while there was no 
significant (P > 0.05) difference (1.22%) in the values 
of the melatonin + caffeine treated hosts relative to 
those of the controls. 
 
 
Table 1  
Effect of treatment on serum total protein and serum 
blood urea nitrogen levels in the rats. 
 
Group (N) Total serum 
protein (mg/ml) 





16.67 ± 0.43 24.68 ± 0.67 
 
Caffeine 
18.78 ± 0.45* 49.27 ± 0.83* 
Melatonin + 
Caffeine 
24.24 ± 0.37#* 24.98 ± 0.69#* 
N=Number of rats per group=5. Values are expressed as 
mean ± SD.                      
* = significantly different from control at P < 0.05. # = 
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Table 2  
Effect of treatment on total brain cholesterol and total 
brain tryptophan levels in the rats. 
 
Group (N) Total brain 
cholesterol 
(mg/g of tissue)  
Total brain 
tryhptophan 
(mg/g of tissue) 
Control 18.41 ± 0.45 97.68 ± 0.65 
Caffeine 65.74 ± 0.53* 13.67 ± 0.31* 
Melatonin + 
Caffeine 
41.93 ± 0.48#* 34.82 ± 0.58#* 
N=Number of rats per group = 5. Values are expressed as 
mean ± SD.  
* = significantly different from control at P < 0.05. # = 
significantly different from caffeine only at P < 0.05. 
 
 
 Table 2 presents the results of treatment on total 
brain cholesterol and brain tryptophan levels in the 
rats. The results for the total brain cholesterol levels 
showed that there was significant (P < 0.05) decrease 
(32.70%) in the values of the caffeine treated hosts 
relative to the controls while there was also a further 
significant (P < 0.05) decrease (57.07%) in values of 
the melatonin + caffeine treated animals relative to 
those of the controls. However, when the values of 
the melatonin + caffeine treated hosts were compared 
to those of caffeine treated animals, the values of the 
melatonin + caffeine treated hosts were lower, that is, 
comparatively decreased by 36.22%. 
 The results for the total brain tryptophan levels 
showed that there was significant (P < 0.05) decrease 
(25.75%) in the values of the caffeine treated rats 
relative to those of the controls while there was 
significant (P < 0.05) increase (89.14%) in the values 
of the melatonin + caffeine treated animals relatively 




 In this study, caffeine alone increased serum total 
serum protein and blood urea nitrogen levels while it 
decreased total brain cholesterol and tryptophan 
levels in the rats. However, interaction of melatonin 
with caffeine increased total protein, and brain 
tryptophan levels, but decreased total brain 
cholesterol and blood urea nitrogen levels in the rats. 
 The effects of caffeine on protein levels could be 
attributed to inhibition of glutamate release due to 
blockade of adenosine receptors. Adenosine receptors 
are linked with interplay of release, reuptake, 
metabolism and excretion of neurotransmitter 
molecules (Eteng et al, 1997). Thus, blockade of 
adenosine receptors inhibited glutamate release and 
reuptake, resulting in low protein synthesis (Obochi, 
2006). Glutamate supplies the amino group required 
for the synthesis of amino acids, and is a substrate for 
glutamine and glutathione synthesis (Julien, 1996). 
This may suggest that caffeine may cause low protein 
synthesis and low protein efficiency, leading to poor 
growth. 
 The effects of caffeine on blood urea nitrogen 
levels could be attributed to the activation of the 
enzyme, xanthine oxidase, which catalyzes the 
oxidation of xanthines to uric acid, which generates 
superoxides, hydrogen peroxides, and free radicals. 
Free radicals are formed by interaction of hydrogen 
peroxide with superoxide anion; the rate of which is 
increased by ions of iron or copper (Julien, 1996). 
Free radicals are constituents that have an unpaired 
electron, generated as by-products of oxidation. 
Addition of an electron to O2 produces a superoxide 
anion radical, O2-, which is reduced by superoxide 
dismutase to peroxide, H2O2, which is toxic at high 
concentrations, and can be reduced to hydroxyl 
radical (∙OH),      [H2O2 + O2-         O2 + HO- 
+ HO∙.] 
 The hydroxyl radical damages cells, DNA and 
neuronal tissue, brain (Reiter, 1995; Reiter et al, 
1995). Mechanisms of action of free radicals on cells, 
DNA and neuronal tissue involves peroxidation and 
chemical modification o the nucleotide bases; the 
damage to proteins is caused by the oxidation of 
sulphydryl group (that is , SH groups are converted to 
S-S groups ); the effect of free radicals on lipids could 
be attributed to the attack on unsaturated fatty acids in 
phospholipid components of membranes, which 
results in the formation of lipid hydroperoxides. 
Hydroperoxidation of membrane lipids increases the 
hydrophobic nature of the lipids, and changes the 
structure of membranes, thereby distorting the normal 
conformation and function (Chan and Tang, 1995). 
Also, lipid hydroperoxides are powerful enzyme 
inhibitors, which inhibit chemical processes, resulting 
in rapid degradation of cells, leading to anemia, and 
inhibition of methaemoglobin which transports 
oxygen (Reiter, 1995).  
 The effects of caffeine on cholesterol levels could  
be attributed to stimulation of phosphoprotein 
phophatase inhibitor – 1 (PP1 – 1), and increased its 
activity thereby inhibiting the activity of 3-hydroxy-
3-mehtylglutaryl CoA (HMG-CoA) reductase, 
resulting in decrease cholesterol synthesis. This effect 
occurs through covalent modification as a result of 
phosphorylation and dephosphorylation. 3-Hydroxy-
3-methylglutaryl-CoA (HMG-CoA) reductase, 
HMGR, is most active in the dephosphorylated state. 
Phosphorylation of the enzyme decreases its activity 
(Chan and Tang, 1995). Also, the effect of caffeine on 
cholesterol could be attributed to stimulation of 
cAMP signaling pathway. Increases in cAMP leads to 
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activation of cAMP-dependent protein kinase, PKA. 
PKA phosphorylates phosphoprotein phophatase 
inhibitor – 1 (PP1 – 1) leading to an increase in its 
activity. Phosphoprotein phosphotase inhibitor – 1 
(PP1 – 1) can inhibit the activity of numerous 
phosphatases including HMG-CoA reductase 
phosphatase, which remove phosphates from HMGR.  
 This maintains HMGR in the phosphorylated and 
inactive state, resulting in decreased activity of 
HMGR, and reduced cholesterol synthesis (Reiter, 
1995). Also, increases in cAMP lead to activation of 
cAMP-dependent protein kinase, PKA, which in turn, 
inhibits HMGR activity, resulting in decreased 
cholesterol synthesis (Reiter, 1995; Chan and Tang, 
1995). The effect of caffeine on cholesterol levels 
could also be attributed to hormonal stimuli, 
particularly lipolytic hormones such as glucagon, 
adrenaline, noradrenaline, adrenocorticotrophin 
hormone (ACTH), growth hormones and 
parathormone, which increase the concentration of 
cAMP, thereby increasing the activity of cAMP-
dependent protein kinase, PKA, which in turn, 
inhibited the activity of HMGR, resulting in 
decreased cholesterol synthesis. However, insulin 
decreases the concentration of cAMP, and thereby 
activates cholesterol synthesis. Thus, the ability of 
insulin to stimulate, and glucagon to inhibit, HMGR 
activity is consistent with the effects of these 
hormones on other metabolic pathways. The basic 
function of these two hormones is to control the 
availability and delivery of energy to all cells of the 
body (Reiter, 1995; Chan and Tang, 1995). Therefore, 
hormones act by influencing a change in 
intracelluloar concentration of cAMP through the 
adenylate cyclase system. Adenylate cyclase 
catalyzes the convesion of ATP to cAMP, thus, 
increasing the intracellular concentration of cAMP. 
The action of cAMP is mainly to activate some 
protein kinases (Reiter, 1995). 
 The effects of caffeine on brain tryptophan levels 
could be attributed to inhibition of 3-hydroxy 
anthranilate oxidase, which catalyzes the rate limiting 
step in the kynurenine-anthranilate pathway, which 
converts tryptophan (an essential amino acid) into 
acetyl CoA. 3-hydroxy kynurenine could not be 
converted to 3-hydroxy-anthranilic acid, resulting in 
accumulation of kynurenine and 3-hydroxy 
kynurenine. These products are converted to 
xanthurenic acid in the extra hepatic tissues, leading 
to tissue wasting and negative nitrogen balance. 
Xanthurenic acid excretion in urine is an index of B6-
deficiency and could lead to anemia (Chatterjee and 
Shinde, 2000). 
 Mechanism of action of caffeine, therefore, 
involves interaction with hormones, peptides and 
receptors on the surface of the plasma membrane to 
generate signals, since these molecules cannot cross 
the plasma membrane (blood-brain-barrier). The 
amplification and subsequent transmission of such 
signals to the cell interiors require the participation of 
a second messenger, usually a cyclic nucleotide, 
cAMP, while the hormones, peptides or receptors 
serve as the first messengers (Eteng et al, 1997). 
 The effect of melatonin on protein levels could be 
attributed to activation of transcriptional promoter 
and enhancer elements used for the control of gene 
expression, which promoted the nucleotide at the 
initiation stage, thereby increasing protein synthesis 
and stimulating the gonadotrophin release, estrogen 
and androgen levels. This could account for use of 
melatonin for improved sex life. 
 The effect of melatonin on blood urea nitrogen 
could be attributed to the antioxidant properties, by 
stimulating the main antioxidant of the brain, 
glutathione peroxidase, which neutralized free 
radicals. This property of melatonin could account for 
its use for longevity and lowering of blood pressure. 
The effect of melatonin on cholesterol levels could be 
attributed to inhibition of the enzyme, HMGR 
activity, which catalyzes the conversion of HMG-
CoA to mevalonate. This enzyme contains SH group 
and requires NADPH as cofactor (supplied by HMP 
pathway) in the conversion of SH group to S-S group 
which increases the hydrophobic properties, thereby 
distorting the lipid components of the membrane 
structure and function, resulting in decreased 
cholesterol synthesis (Chan and Tang, 1995). In this 
study, melatonin acted synergistically with caffeine, 
and decreased cholesterol synthesis, and could be 
used as therapy for hypercholesteromia. Thus, low 
levels of melatonin could be a factor in multiple 
sclerosis, coronary heart disease, sudden infant death 
syndrome, epilepsy and post menopausal osteoporosis 
(Sturner et al, 1990; Brugger et al, 1995; 
Constantinescu et al, 1995). The menopause is 
associated with a decline in melatonin secretion and 
increased calcification (Sandyk, 1994). 
 The effect of melatonin on tryptophan levels could 
be attributed to activation of the enzymes, 
kynureninase and 3-hydroxy anthranilate oxidase, 
which catalyze the conversion of 3-hydroxy 
kynurenine to 3-hydroxy anthranilate and 3-hydroxy 
anthranilate to 2-acroleyl-3-amino fumarate, a 
precursor for the synthesis of niacin and acetyl-CoA. 
Activation of kynureninase and 3-hydroxy 
anthranilate oxidase lead to synthesis of thiamin (B6), 
a vitamin of B complex, thereby preventing 
accumulation of xanthurenic acid and pellagra 
(Chatterjee and Shinde, 2000). 
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 In conclusion, this study has shown that melatonin 
interacted with caffeine to promote synthesis of 
proteins, stimulate gonadotrophin release, estrogen 
and androgen levels, which could be used as oral 
contraceptive for women, and maybe beneficial in the 
treatment of impotence (androgen depression), 
leading to improved reproductive and sex life. The 
interaction of melatonin and caffeine also stimulated 
tryptophan metabolism and thereby preventing 
vitamin B6 deficiency, anemia, negative nitrogen 
balance, tissue wasting, and accumulation of 
xanthurenic acid, thereby promoting sleep. The 
interaction also promoted the reduction of cholesterol 
levels which could be beneficial in the treatment of 
hypercholesterolemia, thereby preventing coronary 
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